$0.14
(Market cap
$493 Mln
Revenue (TTM)
$231 Mln
P/E Ratio
18.4
P/B Ratio
3.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
8.8
-
Debt to Equity
0
-
Book Value
$2.7
-
EPS
$0.5
-
Face value
--
-
Shares outstanding
51,620,066
10 Years Aggregate
CFO
$-514.89 Mln
EBITDA
$-1,038.16 Mln
Net Profit
$-1,212.22 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Puma Biotechnology (PBYI)
| 60.5 | 24.2 | 40.2 | 86.2 | 37.2 | 5.3 | -16.4 |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Puma Biotechnology (PBYI)
| 95.1 | -29.4 | 2.4 | 39.1 | -70.4 | 17.3 | -57.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Puma Biotechnology (PBYI)
|
9.6 | 493.0 | 231.2 | 26.7 | 15.0 | 19.9 | 18.4 | 3.4 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 270.6 | 17,746.8 | 1,054.4 | 755.9 | 5.7 | -- | 20.9 | 10.5 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 |
Shareholding Pattern
View DetailsAbout Puma Biotechnology (PBYI)
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat... adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California. Read more
-
Founder, Chairman, President, CEO & Secretary
Mr. Alan H. Auerbach
-
Founder, Chairman, President, CEO & Secretary
Mr. Alan H. Auerbach
-
Headquarters
Los Angeles, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Puma Biotechnology (PBYI)
What is the current share price of Puma Biotechnology Inc (PBYI) Today?
The share price of Puma Biotechnology Inc (PBYI) is $9.55 (NASDAQ) as of 04-Sep-2026 16:00 EDT. Puma Biotechnology Inc (PBYI) has given a return of 37.17% in the last 3 years.
What is the current PB & PE ratio of Puma Biotechnology Inc (PBYI)?
The P/E ratio of Puma Biotechnology Inc (PBYI) is 18.37 times as on 04-Sep-2026.
The P/B ratio of Puma Biotechnology Inc (PBYI) is 3.44 times as on 04-Sep-2026, a 34 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
9.85 |
2.35 |
2024 |
4.98 |
1.64 |
2023 |
9.63 |
3.89 |
2022 |
96,897.03 |
8.97 |
2021 |
-4.28 |
-51.01 |
What is the 52 Week High and Low of Puma Biotechnology Inc (PBYI)?
The 52-week high and low of Puma Biotechnology Inc (PBYI) are Rs 9.73 and Rs 4.30 as of 06-Sep-2026.
What is the market cap of Puma Biotechnology Inc (PBYI)?
Puma Biotechnology Inc (PBYI) has a market capitalisation of $ 493 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Puma Biotechnology Inc (PBYI)?
Before investing in Puma Biotechnology Inc (PBYI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.